Back to today’s briefing

Story perspectives

Lantern Pharma's AI to Transform Cancer Drug Development

1/28/2025

34 3

Summary

Story summary

Lantern Pharma has unveiled an innovative AI module designed to revolutionize the development of antibody-drug conjugates (ADCs) for cancer treatment. By harnessing its RADR AI platform, the company seeks to slash development costs by 60% and accelerate timelines by up to 50%. With multiple ADC candidates in the pipeline and a partnership with Germany's University of Bielefeld, Lantern is poised to make significant strides in cancer therapy.

History

Historical Context

Lantern Pharma's new AI module for developing antibody-drug conjugates (ADCs) reflects a broader trend in cancer treatment innovation. Since the 1970s, ADCs have emerged as targeted therapies, combining antibodies with cytotoxic drugs to minimize side effects. Historical successes like brentuximab vedotin, approved in 2011, highlight the potential of this approach, paving the way for advancements in personalized cancer therapies.

1 of 2

Story summary

Lantern Pharma has unveiled an innovative AI module designed to revolutionize the development of antibody-drug conjugates (ADCs) for cancer treatment. By harnessing its RADR AI platform, the company seeks to slash development costs by 60% and accelerate timelines by up to 50%. With multiple ADC candidates in the pipeline and a partnership with Germany's University of Bielefeld, Lantern is poised to make significant strides in cancer therapy.

1 / 2